Abivax

ABVX EUR0.01
Create an alert
Sell
€79.30
Buy
€79.50
€1.40 (1.80%)
Last updated today at
Back to dashboard

Company Information

About this company

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Key people

Sylvie L. Gregoire
Independent Chairman of the Board
Kim Kelly
Chief Technical Officer
Fabio Cataldi
Chief Medical Officer
Corinna Zur Bonsen-Thomas
Independent Director
Dominik Hoechli
Independent Director
Troy A. Ignelzi
Independent Director
June H. Lee
Independent Director
Marc De Garidel
Chief Executive Officer, Director
Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Board Secretary
Ida Hatoum
Chief People Officer, Chief Compliance Officer
Jerome Denis
Vice President - Process Development and Manufacturing
Patrick Malloy
Head of Investor Relations
Nadege Briancon-Eris
Senior Vice President, Global Head - Program Management
Maurus de la Rosa
Senior Vice President - Research
Keith Fournier
Senior Vice President - Global Regulatory Affair
Click to see more

Key facts

  • Shares in issue
    79.82m
  • EPIC
    ABVX
  • ISIN
    FR0012333284
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    €6.82bn
  • Employees
    98
  • Exchange
    Euronext Paris
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.